“Rising Adoption of Biologic Therapies in Crohn’s Disease Management”
- Biologic therapies are increasingly utilized in managing Crohn’s disease due to their targeted approach in modulating the immune response, offering improved efficacy over traditional treatments
- The approval of drugs such as AbbVie's Humira (adalimumab) and Janssen’s Stelara (ustekinumab) has expanded treatment options for patients with moderate to severe Crohn’s disease
- For instance, in Journal of Crohn's and Colitis (2022) demonstrated that patients treated with Stelara experienced significant reductions in hospitalization and surgery rates over a one-year period compared to those on standard treatments
- In the U.S., the Mayo Clinic has reported improved remission rates among patients who initiate biologic therapy early in their treatment regimen
- The growing body of clinical evidence supporting the effectiveness and safety of biologics is fostering greater confidence among healthcare providers and patients in adopting these therapies
